PMLiVE has released a collection of white papers from healthcare and pharmaceutical industry agencies and companies. These documents are provided by external organizations and are not approved, checked, or edited by PMLiVE or PMGroup Worldwide Ltd.
Policy and Strategy
October 20, 2026, marked the release of a white paper examining the Most Favored Nation policy and its implications for UK pharmaceutical companies. Written by Jed Avissar and Manca Povsic, the document explores how the policy impacts the industry. Price controls have been a long-standing debate in the sector, and this paper offers an analysis of the specific mechanics of the MFN approach.
Pharma executives are also grappling with how to support talent development while simultaneously adopting artificial intelligence. Elaine Ferguson, the Global President of Inizio Medical, discussed these challenges in a recent interview with Pharma Exec. The discussion centered on the necessity of continuous learning and the strategic integration of AI tools within leadership frameworks.
Partnerships between pharma clients and agencies are often complex. A white paper from September 29 highlights the “partnership paradox,” suggesting that the most effective relationships are built on shared ambition rather than simple transactional business needs. The authors argue that successful collaborations require a deeper connection than just fulfilling specific deliverables on a schedule.
Read Also: Chiesi aids NHS with COPD diagnosis backlog
Effective patient involvement is critical for the success of clinical trials. A recent white paper warns that simply inviting patients to the table is insufficient; they must be properly equipped to contribute meaningfully. The document emphasizes that organizations should focus on preparation to ensure patient input is valuable and impactful.
Long-term engagement with clinical trial participants often presents a behavioral challenge rather than an informational one. A September 24 white paper notes that proactive support from site teams can help participants remain confident and committed throughout the study. Without this ongoing behavioral support, retention rates can suffer significantly.
Finally, a paper from September 21 argues that patients frequently provide honest feedback outside of clinical settings. The text suggests that clinical trial teams should look beyond the clinic walls to gather this unfiltered data, which can help build trust and improve the quality of study results.
